Ocuphire to Present at Five Upcoming Investor/Industry Conferences
21 Nov 2022
Phase 3Phase 1Phase 2Clinical Result
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, founder and CEO will present at several investor conferences in November and December, including the BTIG Ophthalmology Day, Alliance Global Partners (AGP) Biotech Conference, Ophthalmology Innovation Summit (OIS XII), Cantor Dermatology, Ophthalmology & Medtech Conference, and the Planet MicroCap Conference, being held on the following dates:
BTIG Ophthalmology Day – November 29, 2022 Title:Fireside Chat with Ocuphire Pharma (OCUP)Date:Tuesday, November 29, 2022 at 9:30am – 9:55am ETHost:Julian Harrison, MSPresenter:Mina Sooch, MBA, CEO and FounderFormat:Virtual, 1x1 meetings available Alliance Global Partners Biotech Conference – November 30, 2022 Title:Ocuphire Pharma (OCUP) 1x1 MeetingsDate:Wednesday, November 30, 2022Presenter:Ocuphire Management TeamFormat:Virtual, 1x1 meetings available OIS XII San Diego – December 2-3, 2022 Title:Ocuphire Pharma (OCUP) Company PresentationDate:Saturday, December 3, 2022, at 11:40am PTSession:Retina Innovation ShowcasePresenter:Mina Sooch, MBA, CEO and FounderLocation:Hard Rock Hotel, San Diego (in-person)Conf. Registration:Link Cantor Medical & Aesthetic Dermatology, Ophthalmology, & Medtech/Diagnostic Conference – December 8, 2022 Panel Title:Ophthalmology Panel, Ongoing & Upcoming Commercial Stories: Opportunities, Challenges, And Finding The Line Of Sight For SuccessDate:Thursday, December 8, 2022, at 3:45pm – 4:30pm ETHosts:Jennifer Kim and Kristen KluskaPresenter:Mina Sooch, MBA, CEO and FounderLocation:Fountainbleau Hotel in Miami, FL (in-person) Planet MicroCap Conference – December 6-8, 2022 Title:Ocuphire Pharma (OCUP) Company PresentationDate:Thursday, December 8, 2022, at 11:30 am – 12:00 pm ETParticipant:Mina Sooch, MBA, CEO and FounderFormat:Virtual, 1x1 meetings availableWebcast.:Link Virtual CEO Presentation will be on Planet MicroCap's YouTube channel
If you are interested in arranging a 1x1 meeting at one of these events, please contact your conference representative or ir@ocuphire.com. For more details, see the Investor Events section of Ocuphire’s corporate website.
About Ocuphire Pharma
Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders.
The Company’s lead product candidate, Nyxol® eye drops (0.75% phentolamine ophthalmic solution), is a once-daily, preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size and is being developed for three indications, including reversal of pharmacologically induced mydriasis (RM), presbyopia and dim light or night vision disturbances (NVD). Nyxol has been studied in 12 completed clinical trials, including recently reported positive data from the following trials:
MIRA-2 (NCT04620213) and MIRA-3 (NCT05134974) Phase 3 registration trials, and MIRA-4 (NCT05223478) Phase 3 pediatric safety trial for the treatment of RM
VEGA-1 (NCT04675151) Phase 2 trial of Nyxol for treatment of presbyopia, which evaluated both Nyxol as a single agent and Nyxol with low dose pilocarpine (“LDP”) 0.4% as adjunctive therapy
LYNX-1 (NCT04638660) Phase 3 trial of Nyxol for night vision disturbances (NVD)
Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME). APX3330 has been studied in 11 Phase 1 and 2 trials. The Company announced the completion of last patient last visit in late August in Phase 2b ZETA-1 (NCT04692688) trial.
For more information, visit www.ocuphire.com.
Contacts
Corporate Investor Relations Mina Sooch, MBA
CEO & Founder
ir@ocuphire.com Corey Davis, Ph.D.
cdavis@lifesciadvisors.comBret Shapiro
CoreIR
brets@coreir.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.